Medicine
Trandolapril and Verapamil 1 mg/240 mg extended-release tablet
Trandolapril and Verapamil 1 mg/240 mg extended-release tablet is a generic prescription medicine for oral use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F).
Key facts
- Active ingredient (INN)
- Trandolapril and Verapamil
- Brand
- Sold under the generic name
- Strength
- 1 mg/240 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 100 tablets, 1000 tablets, 90 tablets
- Manufacturer
- Glenmark PharmaceuticalsIndia
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C09BB10 Trandolapril and Verapamil
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 25 February 2015
- Identifiers
- RxCUI 897781, 897783, 897844 +1DailyMed set ID 39bad727-af4c-4d20-933b-7f287e88099aNDC 68462-294Application ANDA079135
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, film coated, extended release in 1 bottle | 68462-294-01 | Glenmark PharmaceuticalsIndia | 25 February 2015 |
| 1000 tablet, film coated, extended release in 1 bottle | 68462-294-10 | Glenmark PharmaceuticalsIndia | 25 February 2015 |
| 90 tablet, film coated, extended release in 1 bottle | 68462-294-90 | Glenmark PharmaceuticalsIndia | 25 February 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 22 October 1996 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Trandolapril and Verapamil
Clinical summary
Trandolapril and Verapamil is a fixed-dose combination of an angiotensin converting enzyme inhibitor and a calcium channel blocker indicated for the treatment of hypertension. It is available as extended-release tablets for oral use. MedsAcross supplies Trandolapril and Verapamil for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Trandolapril and VerapamilFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Trandolapril and Verapamil Hydrochloride prescribing information (Glenmark Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Trandolapril and Verapamil 1 mg/240 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.